-
2023-507878-41-00
4
2025-04-25
Acute myeloid leukemia
-
2024-512679-11-00
5
2025-04-25
unborn baby with developmental disorder of the left side of the heart
-
2024-516173-76-01
5
2025-04-22
HER2-positive or HER2-low (incl. ultra-low) early breast cancer
-
2023-505789-27-00
4
2025-04-14
Relapsed or Refractory Non-Hodgkin Lymphoma
-
2024-516802-43-00
9
2025-04-09
metastatic colorectal cancer
-
2023-504904-26-00
5
2025-04-07
Progressive Pulmonary Fibrosis
-
2023-504550-35-00
5
2025-04-03
Atypical Hemolytic Uremic Syndrome (aHUS)
-
2023-508076-11-00
5
2025-04-01
Colon cancer staged T3-4 and/or nodal positive by CT and/or MRI scan w
-
2024-517771-21-00
11
2025-03-31
Acute kidney injury
-
2024-513550-30-00
5
2025-03-28
Newly diagnosed Glioblastoma
-
2024-515445-42-00
5
2025-03-24
Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
-
2023-505311-20-01
5
2025-03-21
Metastatic Non-Small Cell Lung Cancer
-
2023-508307-21-00
5
2025-03-19
Prader-Willi syndrome
-
2024-511994-31-00
4
2025-03-10
Short Bowel Syndrome and Intestinal Failure (SBS-IF) without colon-in-
-
2024-513443-93-00
4
2025-03-10
Recurrent Meningioma without local treatment options (Surgery or Radio
-
2023-510292-65-00
5
2025-02-25
chronic graft-versus-host disease
-
2024-514306-31-00
5
2025-02-13
Pyoderma gangrenosum
-
2022-502352-31-00
5
2025-02-10
Colorectal Cancer (CRC)
-
2024-516440-25-00
1
2025-02-06
KRAS G12D-mutant solid tumors.
-
2024-511037-35-00
4
2025-01-31
Cyclosporine A is a well known medication and is used to prevent rejec
-
2023-505077-32-00
5
2025-01-28
Locally-advanced or metastatic non-squamous non-small cell lung cancer
-
2023-510322-32-00
5
2025-01-27
patients with incurable, metastatic/recurrent head and neck squamous c
-
2024-513852-13-00
5
2025-01-20
KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Col
-
2024-511179-13-00
5
2025-01-13
Myotonic Dystrophy type 1 and type 2 (DM1/DM2)